Mechanism overviews · 29 papers
Peptidoteca
Peptide Reference
Recovery

BPC-157

Also known as: Body Protection Compound-157 · PL 14736

A synthetic pentadecapeptide studied in preclinical models for connective-tissue and gut research.

Written by Peptidoteca Research Desk·Reviewed by Peptidoteca Research Desk·Last reviewed 2026-06-14·4 sources

§ In brief

BPC-157 (also known as Body Protection Compound-157, PL 14736) is a synthetic pentadecapeptide studied in preclinical models for connective-tissue and gut research. It is supplied for laboratory research use only and is not approved for human or veterinary use. Its 15-residue amino-acid sequence is GEPPPGKPADDAGLV.

What is BPC-157?

A synthetic pentadecapeptide studied in preclinical models for connective-tissue and gut research.

BPC-157 is catalogued here as a reference compound for tissue-repair and regenerative research. The entry covers its chemical identity and the public databases that describe it; it is not a usage guide.

How is BPC-157 studied?

BPC-157 appears in the tissue-repair and regenerative literature, primarily in in-vitro and preclinical (animal) models. This page indexes 4 primary papers on BPC-157, each tagged with its study type below. Peptidoteca summarizes the proposed mechanism class and the primary sources rather than human outcomes; for the wider library, see the research library.

Is BPC-157 approved for human use?

No. BPC-157 is supplied for laboratory (in-vitro) research use only. It is not approved by the FDA or any comparable regulator for human or veterinary use, and nothing on this page constitutes medical advice, dosing guidance or a treatment recommendation.

What are the research limitations?

Most available evidence for BPC-157 is preclinical — in-vitro and animal models — and findings in those models do not establish efficacy or safety in humans. Human clinical data is limited or absent, and BPC-157 is not an approved drug. Treat the literature as mechanistic research, not clinical guidance.

§ Primary literature

  1. 1.Yıldırım (2026). Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific Reports.Rodent studyIn a rat model of lower-extremity ischemia-reperfusion injury, BPC 157 was reported to be associated with lower oxidative-stress and apoptosis markers and with better-preserved skeletal muscle structure and reduced fibrosis compared with untreated injured controls. Findings are preclinical and from animals only.
  2. 2.Madzarac G (2026). Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach in Rats. Pharmaceuticals (Basel).Rodent studyIn a rat tracheocutaneous-fistula model that combined the pentadecapeptide BPC 157 with nitric-oxide-system agents, the report described accelerated closure of skin and tracheal defects together with macroscopic and microscopic healing changes relative to control animals.
  3. 3.Yildirim AK (2026). Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. Journal of Clinical Medicine.In-vitroIn an ex-vivo organ-bath (myograph) study using isolated human internal mammary artery rings obtained as residual tissue from coronary artery bypass graft surgeries, BPC 157 was reported to produce a concentration-dependent relaxation of phenylephrine-precontracted rings, greater in endothelium-intact than endothelium-denuded rings, attributed predominantly to an endothelium-dependent nitric-oxide pathway. Findings are limited to isolated human arterial tissue.
  4. 4.Yuan C (2026). From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International Journal of Molecular Sciences.ReviewThis narrative review synthesizes preclinical literature on BPC-157, a synthetic pentadecapeptide, describing reported associations with angiogenesis, collagen synthesis, fibroblast activity, and nitric-oxide-pathway modulation in tissue repair and pain. The authors note that human data remain limited and controlled clinical trials are still needed.
Compound spec
Sequence
GEPPPGKPADDAGLV
Length15 aa
ClassRecovery
CAS137525-51-0
Research vial5 / 10 mg

For in-vitro research only. Not medical, clinical or dosing advice.